Brexpiprazole

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Brexpiprazole

Examples of brand names: Rxulti [EU/DE]

ATC code: N05AX16

Main use (for orientation): Schizophrenia

Documented research summary

A cannabis use disorder cohort does not establish isolated pharmacokinetics or a safe combination. Reliable direct evidence for the pair is absent.

Uncertainties and limitations

Does not establish safety for less-studied cannabinoids or untested formulations/doses.

Do not infer clinical dosage from preclinical effects or enzyme hypotheses.

Research is limited to the specified date and protocol; it is not globally exhaustive. Brand names and authorisations do not constitute a complete current market overview.

Structured assessment

Category: Drug context

Cannabinoid scope: 28 register names in the documented search family; neither 28 individual clinical trials nor a blanket assessment of all cannabinoids.

Evidence status: Insufficient pair-specific data

Mechanism / drug context: Brexpiprazole: CYP3A4/2D6; centrally acting antipsychotic.

Type of supporting material: Medicine information and documented individual review; no positive pair trial

Clinical interpretation: Requires individual assessment by a doctor or pharmacist. Lack of evidence does not establish safety; no dosage or discontinuation advice is provided.

Context: Rexulti, oral brexpiprazole US; schizophrenia, adjunctive MDD treatment and agitation in Alzheimer's dementia (not as needed); US indications. Active D2/D3/5-HT1A partial agonist and 5-HT2A antagonist, not a prodrug. Do not equate CNS/orthostatic effects with a proven cannabis drug–drug interaction.

Drug context and gaps in search results are not measured interactions. The source role below describes which statement the source actually supports.

Source role [C_LABEL_D0124]: Drug context

Statement supported: Supports dosage form, metabolism and/or known risks; alone, it does not substantiate a cannabinoid–drug pair finding.

Source: REXULTI (BREXPIPRAZOLE) TABLET [REMEDYREPACK INC.] [C_LABEL_D0124]

Source role [BMED39819543]: Scope distinction / context

Statement supported: Clinical cohort with cannabis use disorder; no isolated brexpiprazole-pair experiment.

Source: Partial Dopamine D2/3 Agonists and Dual Disorders: A Retrospective-Cohort Study in a Real-World Clinical Setting on Patients with Schizophrenia Spectrum Disorders and Cannabis Use Disorder. [BMED39819543]

Scope of review: Individual research with documented title/abstract screening and targeted review of original sections. This is not exhaustive evidence that interactions are absent.

Unresolved source question: The complete stored individual review, label review, literature screening, conclusion and uncertainties were read. Targeted sections of original information were rechecked; no claim is made that all product information or full texts were completely revalidated.

Separately recorded findings

No separately substantiated finding for this drug–cannabinoid pair is recorded within the documented scope of review. This does not prove that no such study exists anywhere or that the combination is safe.

References and access status

[C_LABEL_D0124] REXULTI (BREXPIPRAZOLE) TABLET [REMEDYREPACK INC.]

Original source / bibliographic reference

Authors: REMEDYREPACK INC.

Year: 2026

Source type: US Structured Product Label

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[BMED39819543] Partial Dopamine D2/3 Agonists and Dual Disorders: A Retrospective-Cohort Study in a Real-World Clinical Setting on Patients with Schizophrenia Spectrum Disorders and Cannabis Use Disorder.

Original source / bibliographic reference

Authors: Trovini G, Lombardozzi G, Kotzalidis GD, Pagano I, Amici E, Giovanetti V, Perrini F, Fagiolini A, De Filippis S.

Year: 2025

Source type: Publication; title and abstract reviewed

DOI: 10.2174/011570159x350599241214042724

PMID: 39819543

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

PubMed Central – archived text

DOI – publisher access (access restrictions may apply)

[C_PR_35427934] A case report of clozapine-treatment-resistant schizophrenia successfully managed with brexpiprazole combination therapy.

Original source / bibliographic reference

Authors: Orsolini L, Bellagamba S, Salvi V, Volpe U.

Year: 2022

Source type: Primary source, abstract read

DOI: 10.1016/j.ajp.2022.103121

PMID: 35427934

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

DOI – publisher access (access restrictions may apply)

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility